Product Specific References | - Nyquist MD, Li Y, Hwang TH, et al. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A. 2013;110(43):1749217497. doi:10.1073/pnas.1308587110.
- Chan SC, Selth LA, Li Y, et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015;43(12):58805897. doi:10.1093/nar/gkv262.
- Dalal K, Che M, Que NS, et al. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Mol Cancer Ther. 2017;16(10):22812291. doi:10.1158/1535-7163.MCT-17-0259.
- Yin Y1, Li R2, Xu K, Ding S2, Li J2, Baek G, Ramanand SG5, Ding S, Liu Z2,, Gao Y, Kanchwala MS6, Li X, Hutchinson R, Liu X, Woldu SL, Xing C6, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV. Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. Cancer Res. 2017 Sep 15;77(18):4745-4754. doi: 10.1158/0008-5472.CAN-17-0164. Epub 2017 Jul 28.
|